García Pascual L, Simó R, Monasterio J, Soriano B, Ortega A M, Mesa J
Sección de Endocrinología, Hospital General Vall d'Hebron, Barcelona.
Rev Clin Esp. 1993 May;192(9):420-3.
In order to analyze the etiologic and pathogenic meaning of platelet activity in diabetic retinopathy, Plasmatic Beta-Thromboglobulin (BTG) has been determined in 42 diabetics without retinopathy, 14 diabetics with non proliferative retinopathy and in 29 health controls. BTG showed higher values in diabetic patients with retinopathy in comparison with diabetics with no retinopathy (46.4 +/- 10.7 versus 37.6 +/- 13.4 ng/ml; p < 0.05 and with controls (31 +/- 18.8; p < 0.005). There were no differences between diabetics with no retinopathy and controls. No relation was found between BTG and the glycemic control grade, neither with lipoproteic profile. In resume, platelet hyperactivity found in patients with retinopathy seems to be an epiphenomenon of the microangiopathic lesion and not an etiologic factor, however this not precludes that it can play a role in the progression on retinal lesions.
为了分析血小板活性在糖尿病视网膜病变中的病因学和发病机制意义，我们测定了42例无视网膜病变的糖尿病患者、14例非增殖性视网膜病变的糖尿病患者以及29例健康对照者的血浆β-血小板球蛋白（BTG）。与无视网膜病变的糖尿病患者相比，有视网膜病变的糖尿病患者的BTG值更高（46.4±10.7对37.6±13.4 ng/ml；p<0.05），与对照组相比也更高（31±18.8；p<0.005）。无视网膜病变的糖尿病患者与对照组之间无差异。未发现BTG与血糖控制水平以及脂蛋白谱之间存在关联。总之，视网膜病变患者中发现的血小板高活性似乎是微血管病变的一种附带现象，而非病因学因素，然而这并不排除它在视网膜病变进展中可能发挥作用。
